Botanix Pharmaceuticals : Investor Presentation

For personal use only

14 March 2022

Investor Presentation

Key highlights

• Release of updated corporate presentation for Botanix's investor roadshow this week and the Switzer Small and Micro cap Conference on the 23rd of March
• The presentation includes updates on the Company's clinical pipeline with near term catalysts and new pipeline opportunities for later stage dermatology assets
• Botanix retains a strong cash position of $16.8 million as at 31 December 2021 with R&D tax concession return pending

Philadelphia PA and Perth Australia, 14 March 2022: Clinical dermatology company, Botanix

Pharmaceuticals Limited (ASX: BOT, "Botanix" or "the Company"), is pleased to release an updated corporate presentation for its investor roadshow taking place this week as well as the Switzer Small and Micro cap conference on Wednesday 23rd March.

The presentation includes an update on the Company's BTX 1801 Phase 2b antimicrobial study which is nearing commencement, the advanced BTX 1702 Phase 1b/2 rosacea study, and the BTX 1204A Phase 1b canine dermatitis study which are completing enrollment in the coming months, as well as new pipeline opportunities for later stage dermatology assets.

The Company's cash position remains strong with $16.8 million as at 31 December 2021 excluding the pending R&D tax concession return. No capital raising is planned as part of this roadshow.

Release authorised by

Vince Ippolito

President and Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology focused company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two separate development platforms - dermatology and antimicrobial products - both of which currently leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol or CBD. Botanix has an exclusive license to use a proprietary drug delivery system (PermetrexTM) for direct skin delivery of active pharmaceuticals in all skin diseases, which it utilises in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

For personal use only

General enquiries	Investor enquiries	Media enquiries
Corporate Communications	Hannah Howlett	Haley Chartres
Botanix Pharmaceuticals	WE Communications	H^CK
P: [phone]	P: [phone]	P: [phone]
[e-mail]	[e-mail]	[e-mail]

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

ersonal use only

Botanix Overview

March 2022

Operations:

3602 Horizon Drive, Suite 160 King of Prussia PA 19041

Corporate Office:

Level 1, 50 Angove Street North Perth W. Australia 6006

US focused clinical stage dermatology company

Targeting billion-dollar markets with novel products

ersonal use only

Pharmaceutical focus

Topically driven

Significant markets

World-class team

Near-term catalysts

New treatments for common skin diseases (such as rosacea and acne), and life threatening bacterial infections

Dermatologists prefer creams and gels as first line treatment and our skin delivery technology (Permetrex™), provides a new and effective solution

Targeting multi-billion dollar markets, with no new acting products approved by FDA, in more than 20 years for conditions like acne and rosacea

US based clinical development and commercialisation team, with recent billion dollar exits to big pharma

Upcoming readout of Phase 1b/2 rosacea study, start of Phase 2b antimicrobial study, Phase 1b canine dermatitis data readout and announcement of new pipeline opportunities

2

www.botanixpharma.com

Corporate

Corporate Overview

ersonal use only

ASX: BOT Trading Information

Share price	A$0.061
6-month low / high	A$0.061/0.115
Shares outstanding	973,142,074
Market Capitalisation	A$59.36
Cash (31 Dec 2021)	A$ 16.8m
Debt (31 Dec 2021)	Nil
Enterprise value	A$ 41.6m

Substantial Shareholders

Shareholder	%
Matt Callahan, Founder and Executive Director	7.27%
Caperi Pty Ltd, Co-Founder	5.4%

Share price performance (last 6 months)

Price (A$)	Volume (m)
$0.16	0.0
	0.0
$0.12
	0.0
$0.08	0.0
	0.0
$0.04
	0.0
$0.00	0.0
Mar-21	Jun-21

3

www.botanixpharma.com